Edition:
United States

People: AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,114.00GBp
5:15am EST
Change (% chg)

76.50p (+1.89%)
Prev Close
4,037.50p
Open
4,058.00p
Day's High
4,119.00p
Day's Low
4,052.00p
Volume
723,104
Avg. Vol
2,838,722
52-wk High
5,505.00p
52-wk Low
3,680.00p

Soriot, Pascal 

Mr. Pascal Soriot is Executive Director and Chief Executive Officer of AstraZeneca PLC. Pascal was appointed as a Director and CEO in October 2012. From 2010 to September 2012, he served as Chief Operating Officer of Roche AG’s pharmaceuticals division. Prior to that, he was CEO of Genentech, a biologics business, and led its successful merger with Roche. He joined the pharmaceutical industry in 1986 and has worked in senior management roles throughout the world in a number of major companies. He brings to AstraZeneca a significant breadth of experience in both established and emerging markets, strength of strategic thinking, a successful track record of managing change and putting strategy into operation, and the ability to lead a diverse organisation, having lived in Australia, Japan, the US and Europe. He is a doctor of veterinary medicine (École Nationale Vétérinaire d’Alfort, Maisons-Alfort) and holds an MBA from HEC, Paris.

Basic Compensation

Total Annual Compensation, GBP 3,209,000
Restricted Stock Awards, GBP --
Long-Term Incentive Plans, GBP 4,723,000
All Other, GBP 465,000
Fiscal Year Total, GBP 8,397,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leif Johansson

609,000

Pascal Soriot

8,397,000

Marc Dunoyer

5,955,000

Fiona Cicconi

--

Sean Bohen

--

Pam Cheng

--
As Of  30 Dec 2015